Wilmington Savings Fund Society FSB Acquires New Shares in Sana Biotechnology, Inc. (NASDAQ:SANA)

Wilmington Savings Fund Society FSB purchased a new stake in Sana Biotechnology, Inc. (NASDAQ:SANA) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 6,883 shares of the company’s stock, valued at approximately $29,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Stifel Financial Corp bought a new stake in shares of Sana Biotechnology in the third quarter worth about $43,000. EP Wealth Advisors LLC acquired a new position in shares of Sana Biotechnology in the 3rd quarter valued at approximately $45,000. Blue Trust Inc. increased its stake in Sana Biotechnology by 1,246.6% during the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock worth $55,000 after purchasing an additional 12,154 shares in the last quarter. Cornercap Investment Counsel Inc. acquired a new stake in Sana Biotechnology during the 3rd quarter worth approximately $67,000. Finally, Algert Global LLC bought a new position in Sana Biotechnology in the second quarter valued at approximately $73,000. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Stock Down 1.2 %

Shares of SANA stock opened at $1.63 on Tuesday. Sana Biotechnology, Inc. has a 12 month low of $1.55 and a 12 month high of $12.00. The company’s fifty day simple moving average is $2.93 and its 200-day simple moving average is $4.47. The firm has a market cap of $363.93 million, a PE ratio of -1.16 and a beta of 1.33.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. On average, equities analysts predict that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on SANA. JMP Securities downgraded shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Sana Biotechnology in a report on Wednesday, November 27th.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.